Antibiotic-Resistant Pseudomonas aeruginosa: Current Challenges and Emerging Alternative Therapies DOI Creative Commons

Minqi Hu,

Song Lin Chua

Microorganisms, Journal Year: 2025, Volume and Issue: 13(4), P. 913 - 913

Published: April 16, 2025

Antibiotic-resistant Pseudomonas aeruginosa is a pathogen notorious for its resilience in clinical settings due to biofilm formation, efflux pumps, and the rapid acquisition of resistance genes. With traditional antibiotic therapy rendered ineffective against infections, we explore alternative therapies that have shown promise, including antimicrobial peptides, nanoparticles quorum sensing inhibitors. While these approaches offer potential, they each face challenges, such as specificity, stability, delivery, which require careful consideration further study. We also delve into emerging strategies, bacteriophage CRISPR-Cas gene editing could enhance targeted treatment personalized medicine. As most them are currently experimental stages, highlight need trials additional research confirm their feasibility. Hence, insights new therapeutic avenues help address pressing issue antibiotic-resistant aeruginosa, with an eye toward practical applications future healthcare.

Language: Английский

Correction: Intricate interplay of CRISPR-Cas systems, anti-CRISPR proteins, and antimicrobial resistance genes in a globally successful multi-drug resistant Klebsiella pneumoniae clone DOI Creative Commons
Jianping Jiang, Astrid V. Cienfuegos-Gallet, Tengfei Long

et al.

Genome Medicine, Journal Year: 2025, Volume and Issue: 17(1)

Published: Feb. 24, 2025

Language: Английский

Citations

1
First report of blaVEB-3 and blaKPC-2 coexistence with a novel blaKPC-2 transposon in Klebsiella michiganensis DOI Creative Commons
Yu-Xia Zhong, Peibo Yuan, Li Dai

et al.

Infection Genetics and Evolution, Journal Year: 2025, Volume and Issue: unknown, P. 105740 - 105740

Published: March 1, 2025

Klebsiella michiganensis, an emerging opportunistic pathogen, poses public health risks due to its increasing multidrug resistance (MDR), especially carbapenems. A 46-year-old man with pulmonary fibrosis was hospitalized in Guangzhou, China, for worsening pneumonia. multidrug-resistant K. michiganensis strain (YK6) isolated from his sputum before treatment. The characterized using MALDI-TOF mass spectrometry, antimicrobial susceptibility testing (AST), and whole genome sequencing (WGS). Targeted therapy guided by AST successfully resolved the infection. YK6 exhibited carbapenems, β-lactam/β-lactamase inhibitors, cephalosporins, aminoglycosides, quinolones, except colistin tigecycline. Genomic analysis revealed a 41.9-kb MDR island intact I-E CRISPR-Cas system on chromosome, along two plasmids: IncFIA/IncFII plasmid pYK6-1 carrying blaKPC-2 IncC pYK6-2 harboring blaVEB-3. novel blaKPC-2-transposon identified, consisting of non-Tn4401 element (NTE)-like structure (Tn3-ISKpn27-blaKPC-2-ΔISKpn6-korC) flanked inversely oriented ISKpn19-tnpM-tnpR elements 31-bp inverted repeats never reported, configuration did not reported previously. Furthermore, blaVEB-3 genetic environment featured unique cassette: IS26-IS6100-blaVEB-3-tnp-ISAs1-qacEΔ1-sul1-ISCR1. An additional ISAs1 insertion between tnpF-like integrase qacEΔ1 distinguishes it similar blaVEB-3-harboring cassettes. region likely originated homologous recombination mediated IS26 Tn5403, which flank gene cassette. To our knowledge, this is first report concurrent transposon structure. These findings highlight urgent need enhanced surveillance prevent treatment failures.

Language: Английский

Citations

0
Antibiotic-Resistant Pseudomonas aeruginosa: Current Challenges and Emerging Alternative Therapies DOI Creative Commons

Minqi Hu,

Song Lin Chua

Microorganisms, Journal Year: 2025, Volume and Issue: 13(4), P. 913 - 913

Published: April 16, 2025

Antibiotic-resistant Pseudomonas aeruginosa is a pathogen notorious for its resilience in clinical settings due to biofilm formation, efflux pumps, and the rapid acquisition of resistance genes. With traditional antibiotic therapy rendered ineffective against infections, we explore alternative therapies that have shown promise, including antimicrobial peptides, nanoparticles quorum sensing inhibitors. While these approaches offer potential, they each face challenges, such as specificity, stability, delivery, which require careful consideration further study. We also delve into emerging strategies, bacteriophage CRISPR-Cas gene editing could enhance targeted treatment personalized medicine. As most them are currently experimental stages, highlight need trials additional research confirm their feasibility. Hence, insights new therapeutic avenues help address pressing issue antibiotic-resistant aeruginosa, with an eye toward practical applications future healthcare.

Language: Английский

Citations

0